DJIA 17,678.23 -40.31 -0.23%
NASDAQ 4,863.36 -13.16 -0.27%
S&P 500 2,056.15 -4.90 -0.24%
market minute promo

Novartis (NYSE: NVS)

99.56 -0.80 (-0.80%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

NVS $99.56 -0.80%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $99.98
Previous Close $100.36
Daily Range $99.05 - $99.99
52-Week Range $81.07 - $103.50
Market Cap $238.8B
P/E Ratio 27.12
Dividend (Yield) $2.82 (2.4%)
Ex-Dividend Date
Dividend Pay Date
03/02/15
01/01/70
Volume 984,200
Average Daily Volume 1,475,404
Current FY EPS $5.31

Sector

Healthcare

Industry

Drug Makers

Novartis (NVS) Description

Operates in the business of patent-protected and generic pharmaceuticals as well as consumer health products. Website: http://www.novartis.com/

News & Commentary

Is It Time for GlaxoSmithKline plc to Change Management?

GlaxoSmithKline's share price has stagnated under CEO Andrew Witty. Is it time for a change?

Ligand Pharmaceuticals: Biotech's Jack Of All Trades

Juno: Trying To Justify A $5.5B Valuation For A Year-Old Company

Is This The Biggest Threat to Isis Pharmaceuticals Stock?

Isis Pharmaceuticals has garnered a massive premium based on the potential of its antisense drug pipeline. With numerous companies entering the rare disease field, though, Isis' drugs might face stiff competition. So are investors being overly optimistic?

Novartis Reports Positive Data on Psoriasis Drug Cosentyx - Analyst Blog

11 Promising New Drugs Expected to Make Billions in Sales

This Market Could Grow 6250% in 10 Years

With the regulatory pathway cleared, the biosimilars market is poised to turn into a gold mine, growing up to 6,250% in 10 years. Here's where to stake your claim.

CELG Stock - Here's Why Celgene Is Worth Snapping Up

Dividend Stocks: 2 to Avoid, 1 to Buy

Motley Fool contributor Todd Campbell offers up two dividend-paying healthcare stocks to avoid and one that could be a good buy for long-term income investors.

Novartis International AG: New Novartis data shows Cosentyx is significantly superior to Stelara and

Novartis International AG: New Novartis data shows Cosentyx is significantly superior to Stelara and clears skin (PASI 90

See More NVS News...

NVS's Top Competitors

NVS $99.56 (-0.80%)
Current stock: NVS
JNJ $100.14 (-0.20%)
Current stock: JNJ
MRK $57.60 (-1.13%)
Current stock: MRK
GSK $46.66 (-1.46%)
Current stock: GSK